Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11562MR)

This product GTTS-WQ11562MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11562MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7433MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ1344MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ15821MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ5010MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ367MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ8440MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ9333MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ1741MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW